Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769478 · ClinicalTrials.gov registry record · Phase 1
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
A Phase 1 study of Botulism and Iatrogenic Botulism, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT05769478: Completed Phase 1 study of Botulism and Iatrogenic Botulism, sponsored by Wake Forest University Health Sciences.
NCT05769478 is a Phase 1 study of Botulism and Iatrogenic Botulism that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05769478, a Phase 1 study of Botulism and Iatrogenic Botulism, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
if amifampridine can improve neuromuscular transmission in muscles previously injected with OnabotulinumtoxinA (BTX-A)
Primary Outcome
Wilcoxon's test for paired data will be used to analyze baseline and post-treatment percent abnormal pairs
Conditions Studied
Interventions
- DRUG Amifampridine
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2024-10-29 |
| Phase | Phase 1 |
What the finished NCT05769478 record still lists
NCT05769478 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Botulism appearing as the primary indexed condition, and to 1 intervention - of which Amifampridine is the first listed.
NCT05769478 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05769478 about?
NCT05769478 is a clinical study titled "Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA". if amifampridine can improve neuromuscular transmission in muscles previously injected with OnabotulinumtoxinA (BTX-A)
What is the current status of trial NCT05769478?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-09-15. Estimated completion is 2024-10-29.
What conditions does trial NCT05769478 study?
This clinical trial studies the following conditions: Botulism, Iatrogenic Botulism.
What interventions are being tested in trial NCT05769478?
The interventions under investigation include: Amifampridine (DRUG).
Who is sponsoring clinical trial NCT05769478?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05769478 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Botulism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05769478's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI